Production & Sales

Nexus Pharmaceuticals gets FDA nod for Arsenic Trioxide injection in 10mg per 10mL vial

Nexus Pharmaceuticals has announced the immediate availability of Arsenic Trioxide Injection in 10mg per 10mL vial in the US.

AstraZeneca to sell Synagis US rights to Sobi for $1.5bn

AstraZeneca has agreed to offload the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a cash-cum-stock deal worth $1.5bn.

Ferring launches Nocdurna in US to treat nocturia due to NP

Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

AstraZeneca has agreed to offload its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for $350m.

Quotient Sciences extends formulation and manufacturing operations in UK

Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading facility, UK.

Janssen recalls Ortho-Novum tablets over incorrect Veridate dispenser instructions

Janssen Pharmaceuticals is voluntary recalling one lot of Ortho-Novum 1/35 (norethindrone/ethinyl estradiol) tablets and two lots of Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol) tablets to the pharmacy level.

GW announces US launch of cannabinoid medicine for seizures

GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.

Grünenthal to buy AstraZeneca’s European rights to two drugs for $922m

German pharma company Grünenthal has agreed to acquire certain rights to AstraZeneca’s Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) for a sum of up to $922m.

EQT offers to buy Karo Pharma for $654m

Private equity firm EQT has proposed to acquire 100% of Karo Pharma, a Swedish pharma company, for around SEK5.97bn ($654m).